SCHEMBL802796

SCHEMBL802796

C=CC1CCC(c2ccc(-c3ccc(C)c(F)c3F)cc2)CC1

nearest known ligand 0.33

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 3/20 0.33
CYP2C9 P11712 2/20 0.33
APP P05067 2/20 0.33
CYP2D6 P10635 1/20 0.32
CYP2C19 P33261 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8933220 0.91 CYP3A4 (0.37) CYP3A4CYP2C9APPCYP2D6CYP2C19
SCHEMBL26167206 0.88 CYP3A4 (0.38) CYP3A4CYP2C9APPCYP2D6CYP2C19
SCHEMBL8959172 0.88 CYP3A4 (0.35) CYP3A4CYP2C9APPCYP2D6CYP2C19
SCHEMBL8935080 0.88 ALOX5AP (0.33)
SCHEMBL11953548 0.86 CYP3A4 (0.35) CYP3A4CYP2C9APPCYP2D6CYP2C19
SCHEMBL18234074 0.85 CYP3A4 (0.31) CYP3A4CYP2C9APPCYP2D6CYP2C19
SCHEMBL12379817 0.85 DGAT1 (0.34) CYP3A4CYP2C9APPCYP2D6CYP2C19
SCHEMBL18134255 0.85 DGAT1 (0.34) CYP3A4CYP2C9APPCYP2D6CYP2C19
SCHEMBL9970178 0.85 CYP3A4 (0.32) CYP3A4CYP2C9APPCYP2D6CYP2C19
SCHEMBL4549716 0.85 CYP3A4 (0.32) CYP3A4CYP2C9APPCYP2D6CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 309 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12043782-B2 Liquid crystalline medium MERCK PATENT GMBH (DE) 2024-07-23 US disclosed
WO-2024133363-A1 LIQUID-CRYSTAL MEDIUM MERCK PATENT GMBH (DE) 2024-06-27 WO disclosed
US-20240067879-A1 Liquid-crystal medium MERCK PATENT GMBH (DE) 2024-02-29 US disclosed
US-20240067879-A1 Liquid-crystal medium MERCK PATENT GMBH (DE) 2024-02-29 US disclosed
EP-4306615-A1 LIQUID-CRYSTAL MEDIUM Merck Patent GmbH (DE) 2024-01-17 EP disclosed
US-11873438-B2 Liquid-crystal medium MERCK PATENT GMBH (DE) 2024-01-16 US disclosed
EP-4279565-A2 THIOPHENE COMPOUND, LIQUID-CRYSTALLINE MEDIUM AND LIQUID-CRYSTAL DISPLAY COMPRISING THE SAME Merck Patent GmbH (DE) 2023-11-22 EP disclosed
US-20230357637-A1 LIQUID-CRYSTAL MEDIUM MERCK PATENT GMBH (DE) 2023-11-09 US disclosed
US-20230357637-A1 LIQUID-CRYSTAL MEDIUM MERCK PATENT GMBH (DE) 2023-11-09 US disclosed
EP-3679111-B1 LIQUID-CRYSTALLINE MEDIUM AND LIQUID-CRYSTAL DISPLAY COMPRISING THE SAME MERCK PATENT GMBH (DE) 2023-11-01 EP disclosed
US-20090141215-A1 POLYMERIZABLE COMPOUNDS MERCK PATENT GESELLSCHAFT (DE) 2009-06-04 US disclosed
US-20090103011-A1 LIQUID-CRYSTAL MEDIUM MERCK PATENT GESELLSCHAFT (DE) 2009-04-23 US disclosed
US-20080308768-A1 Liquid Crystalline Medium MERCK PATENT GMBH (DE) 2008-12-18 US disclosed
US-7425355-B2 Liquid-crystalline medium MERCK PATENT GMBH (DE) 2008-09-16 US disclosed
US-20080197319-A1 LIQUID-CRYSTALLINE MEDIUM MERCK PATENT GESELLSCHAFT (DE) 2008-08-21 US disclosed
US-20080193681-A1 Liquid-Crystal Medium MERCK PATENT GMBH (DE) 2008-08-14 US disclosed
US-7371437-B2 Liquid-crystalline medium MERCK PATENT GMBH (DE) 2008-05-13 US disclosed
US-7335403-B2 Liquid-crystalline medium MERCK PATENT GMBH (DE) 2008-02-26 US disclosed
US-20070080324-A1 mixture of polar compounds of negative dielectric anisotropy; electro-optical display with active-matrix addressing based on the ECB(electrically controlled birefringence), PALC (positive charge assisted leakage current) or IPS ( in plane switching) effect MERCK PATENT GMBH (DE) 2007-04-12 US disclosed
US-20070051920-A1 Liquid-crystalline medium MERCK PATENT GMBH (DE) 2007-03-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090141215-A1 POLYMERIZABLE COMPOUNDS VCL, LCP1, LPXN CYP3A4 3971/4885CYP2C9 4408/4885APP 723/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.